Results 61 to 70 of about 338,185 (301)
Diagnosis and Management of COVID-19 Disease [PDF]
, 2020 SARS-CoV-2 is a novel coronavirus that was identified in late 2019 as the causative agent of COVID-19 (aka coronavirus disease 2019). On March 11, 2020, the World Health Organization (WHO) declared the world-wide outbreak of COVID-19 a pandemic.
Carlos, Graham +5 more
core +1 more source
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
Respiratory Research, 2021 Background The COVID-19 pandemic has affected the world extraordinarily. This disease has a potential to cause a significantly severe course of disease leading to respiratory complications, multiple organ failure and possibly death.
Alina Kröker, Madara Tirzīte
doaj +1 more source
Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department [PDF]
, 2020 As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise.
Brown, Cortlyn +2 more
core
Drug Repurposing in the Treatment of COVID-19
Bezmialem Science, 2020 The use of drugs that have been previously defined for certain indications in new indications is defined as the repurposing/repositioning of the drug. The requirement of all clinical research steps that starts from healthy volunteers, due to the slowness of new drug discovery, longer time to reach the market, and high cost to develop a new drug, make ...
Mehmet SOYLU +2 more
openaire +4 more sources
Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2 [PDF]
, 2020 Background and purpose Infections with coronaviruses are not always confined to the respiratory tract and various neurological manifestations have been reported.
Boon, Paul +6 more
core +2 more sources
Repurposing the drug, ivermectin, in COVID-19: toxicological points of view
European Journal of Medical Research, 2022 The global COVID-19 pandemic has affected the world’s population by causing changes in behavior, such as social distancing, masking, restricting people’s movement, and evaluating existing medication as potential therapies.
Farshad M. Shirazi +5 more
doaj +1 more source
Frontiers in Pharmacology, 2022 COVID-19 is a highly contagious respiratory disease, which mainly affects the lungs. Critically ill patients are easily complicated by cytokine storms, acute respiratory distress syndrome (ARDS), and respiratory failure, which seriously threaten their ...
Hao Shen +14 more
doaj +1 more source
Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics
Pharmaceutics, 2021 An increasing number of clinical studies worldwide are investigating the repurposing of antiviral, immune-modulatory, and anti-inflammatory agents to face the coronavirus disease-19 (COVID-19) pandemic.
Matteo Puccetti +3 more
doaj +1 more source
2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission. [PDF]
, 2020 With the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in coronavirus disease 2019 (COVID-19), corporate entities, federal, state, county, and city governments, universities, school districts, places of worship,
Coil, David A +5 more
core +2 more sources
Reciprocal control of viral infection and phosphoinositide dynamics
FEBS Letters, EarlyView.Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley +1 more source